RxDoctor Payments Data

Jigar Patel, MD

Interventional Cardiology · Ocala, FLNPI 1114068871

Payments from drug & device makers

$18,346in general payments, 2019–2025

Across 669 payments — averaging $27.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$2K
  • Medtronic$2K
  • Pfizer$1K
  • Abiomed$966
  • Abbott$950
  • AstraZeneca$946
  • plus $10K from 38 others

What the payments were for

  • Travel & lodging$9415%
  • Food & beverage$17,27894%
  • Education$1271%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,346 in reported general payments places this provider in the 65th percentile of 623 interventional cardiology providers in Florida.

See all interventional cardiology providers in Florida

Medicare billing

Part B allowed, 2024
$1,286,631
Medicare patients
1,219
Services billed
7,363

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban751$872,734
EntrestoSacubitril/Valsartan294$385,561
XareltoRivaroxaban187$179,156
FarxigaDapagliflozin Propanediol109$122,872
JardianceEmpagliflozin71$94,878
Repatha SureclickEvolocumab61$69,350
BrilintaTicagrelor70$66,071
VascepaIcosapent Ethyl86$55,640
CorlanorIvabradine Hcl14$16,626
Icosapent Ethyl23$10,667
NexletolBempedoic Acid14$10,554
Praluent PenAlirocumab13$9,429
Dabigatran EtexilateDabigatran Etexilate Mesylate30$8,518
Atorvastatin Calcium702$7,568
ClopidogrelClopidogrel Bisulfate658$6,144

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$1,028$872,734751 claims
NovartisEntresto$332$385,561294 claims
AstraZenecaFarxiga, Brilinta$946$188,943179 claims
Johnson & JohnsonXarelto$732$179,156187 claims
Boehringer IngelheimJardiance$654$94,87871 claims
AmgenCorlanor$877$16,62614 claims
Esperion Therapeutics, Inc.Nexletol$32$10,55414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 623 interventional cardiology providers in Florida.

Other interventional cardiology in Ocala

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →